{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:00:28Z","timestamp":1792839628660,"version":"4.5.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014923","name":"CymaBay Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014923","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018262","name":"Intercept Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018262","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019120","name":"Otsuka America","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019120","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.cgh.2019.09.050","type":"journal-article","created":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T13:57:02Z","timestamp":1570715822000},"page":"1170-1178.e6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":97,"title":["Long-Term Obeticholic Acid Therapy Improves Histological Endpoints in Patients With Primary Biliary Cholangitis"],"prefix":"10.1016","volume":"18","author":[{"given":"Christopher L.","family":"Bowlus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Pockros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas E.","family":"Kremer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Par\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa M.","family":"Forman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost P.H.","family":"Drenth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen D.","family":"Ryder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Terracciano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuying","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Liberman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Pencek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uche","family":"Iloeje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leigh","family":"MacConell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Bedossa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2019.09.050_bib1","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.cld.2018.03.008","article-title":"Liver biopsy in primary biliary cholangitis: indications and interpretation","volume":"22","author":"Tan","year":"2018","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.cgh.2019.09.050_bib2","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/hep.30145","article-title":"Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases","volume":"69","author":"Lindor","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2019.09.050_bib3","first-page":"61","article-title":"Natural history and management of primary biliary cirrhosis","volume":"4","author":"Al-Harthy","year":"2012","journal-title":"Hepat Med"},{"key":"10.1016\/j.cgh.2019.09.050_bib4","first-page":"154","article-title":"Update on new drugs and those in development for the treatment of primary biliary cholangitis","volume":"14","author":"Bahar","year":"2018","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2019.09.050_bib5","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/hep.510230108","article-title":"Time course of histological progression in primary biliary cirrhosis","volume":"23","author":"Locke","year":"1996","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2019.09.050_bib6","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1053\/j.gastro.2014.08.029","article-title":"Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study","volume":"147","author":"Lammers","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2019.09.050_bib7","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.gastro.2005.12.029","article-title":"Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid","volume":"130","author":"Pares","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2019.09.050_bib8","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1038\/ajg.2010.216","article-title":"Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis","volume":"105","author":"Kumagi","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2019.09.050_bib9","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1053\/gast.2002.31880","article-title":"Primary biliary cirrhosis: incidence and predictive factors of cirrhosis development in ursodiol-treated patients","volume":"122","author":"Corpechot","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2019.09.050_bib10","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A\u00a0placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2019.09.050_bib11","series-title":"OCALIVA [package insert]","year":"2018"},{"key":"10.1016\/j.cgh.2019.09.050_bib12","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1021\/jm025529g","article-title":"6alpha-ethyl-chenodeoxycholic\u00a0acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity","volume":"45","author":"Pellicciari","year":"2002","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.cgh.2019.09.050_bib13","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1002\/hep.29569","article-title":"A\u00a0randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis","volume":"67","author":"Kowdley","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2019.09.050_bib14","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1053\/j.gastro.2014.12.005","article-title":"Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid","volume":"148","author":"Hirschfield","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2019.09.050_bib15","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S2468-1253(19)30094-9","article-title":"Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study","volume":"4","author":"Trauner","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2019.09.050_bib16","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2019.09.050_bib17","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1016\/S0618-8278(19)30006-4","article-title":"Positive results from REGENERATE: a phase 3 international, randomized, placebo-controlled study evaluating obeticholic acid treatment for NASH","volume":"70","author":"Younossi","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2019.09.050_bib18","doi-asserted-by":"crossref","first-page":"E178","DOI":"10.1111\/hepr.12746","article-title":"Liver fibrosis progression predicts survival in patients with primary biliary cirrhosis","volume":"47","author":"Namisaki","year":"2017","journal-title":"Hepatol Res"},{"key":"10.1016\/j.cgh.2019.09.050_bib19","first-page":"S263","article-title":"Histological stage is relevant for risk stratification in primary biliary cirrhosis","volume":"62","author":"Carbone","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2019.09.050_bib20","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/hep.22428","article-title":"Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis","volume":"48","author":"Corpechot","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2019.09.050_bib21","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.humpath.2012.09.017","article-title":"Evaluation of a new histologic staging and grading system for primary biliary cirrhosis in comparison with classical systems","volume":"44","author":"Kakuda","year":"2013","journal-title":"Hum Pathol"},{"key":"10.1016\/j.cgh.2019.09.050_bib22","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis","volume":"67","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2019.09.050_bib23","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1440-1827.2009.02500.x","article-title":"Application of a new histological staging and grading system for primary biliary cirrhosis to liver biopsy specimens: interobserver agreement","volume":"60","author":"Nakanuma","year":"2010","journal-title":"Pathol Int"},{"key":"10.1016\/j.cgh.2019.09.050_bib24","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.hep.2003.09.022","article-title":"Sampling variability of liver fibrosis in chronic hepatitis C","volume":"38","author":"Bedossa","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2019.09.050_bib25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0147804","article-title":"Continuous grading of early fibrosis in NAFLD using label-free imaging: a proof-of-concept study","volume":"11","author":"Pirhonen","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.cgh.2019.09.050_bib26","first-page":"445","article-title":"Evaluation of liver fibrosis: \"something old, something new...\"","volume":"29","author":"Almpanis","year":"2016","journal-title":"Ann Gastroenterol"},{"key":"10.1016\/j.cgh.2019.09.050_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0199166","article-title":"Second harmonic generation microscopy provides accurate automated staging of liver fibrosis in patients with non-alcoholic fatty liver disease","volume":"13","author":"Chang","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.cgh.2019.09.050_bib28","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1038\/s41598-018-21179-2","article-title":"Quantitative assessment of liver fibrosis (qFibrosis) reveals precise outcomes in Ishak \"stable\" patients on anti-HBV therapy","volume":"8","author":"Sun","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.cgh.2019.09.050_bib29","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/jvh.12835","article-title":"Improved performance of quantitative collagen parameters versus standard histology in longitudinal assessment of nonadvanced liver fibrosis for chronic hepatitis B","volume":"25","author":"Wang","year":"2018","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.cgh.2019.09.050_bib30","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1093\/ajcp\/aqx104","article-title":"Second harmonic generation reveals subtle fibrosis differences in adult and pediatric nonalcoholic fatty liver disease","volume":"148","author":"Liu","year":"2017","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.cgh.2019.09.050_bib31","first-page":"1037","article-title":"Quantitative fibrosis parameters highly predict esophageal-gastro varices in primary biliary cirrhosis","volume":"20","author":"Wu","year":"2016","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.cgh.2019.09.050_bib32","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/hep.510290301","article-title":"Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis","volume":"29","author":"Angulo","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2019.09.050_bib33","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1053\/gast.1996.v110.pm8613058","article-title":"Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis","volume":"110","author":"Lindor","year":"1996","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2019.09.050_bib34","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.329","article-title":"Obeticholic acid, a selective farnesoid X receptor agonist, regulates bile acid homeostasis in sandwich-cultured human hepatocytes","volume":"5","author":"Zhang","year":"2017","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.cgh.2019.09.050_bib35","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19072069","article-title":"Update on FXR biology: promising therapeutic target?","volume":"19","author":"Han","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.cgh.2019.09.050_bib37","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1440-1827.2009.02500.x","article-title":"Application of a new histological staging and grading system for primary biliary cirrhosis to liver biopsy specimens: interobserver agreement","volume":"60","author":"Nakanuma","year":"2010","journal-title":"Pathol Int"},{"key":"10.1016\/j.cgh.2019.09.050_bib38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0199166","article-title":"Second harmonic generation microscopy provides accurate automated staging of liver fibrosis in patients with non-alcoholic fatty liver disease","volume":"13","author":"Chang","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.cgh.2019.09.050_bib39","first-page":"445","article-title":"Evaluation of liver fibrosis: \"something old, something new...\"","volume":"29","author":"Almpanis","year":"2016","journal-title":"Ann Gastroenterol"},{"key":"10.1016\/j.cgh.2019.09.050_bib40","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1002\/hep.29090","article-title":"Dual-photon microscopy-based quantitation of fibrosis-related parameters (q-FP) to model disease progression in steatohepatitis","volume":"65","author":"Wang","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2019.09.050_bib41","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.jhep.2014.02.015","article-title":"qFibrosis: a fully-quantitative innovative method incorporating histological features to facilitate accurate fibrosis scoring in animal model and chronic hepatitis B patients","volume":"61","author":"Xu","year":"2014","journal-title":"J\u00a0Hepatol"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356519311061?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356519311061?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:31:30Z","timestamp":1761543090000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356519311061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["S1542356519311061"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2019.09.050","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-Term Obeticholic Acid Therapy Improves Histological Endpoints in Patients With Primary Biliary Cholangitis","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2019.09.050","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by the AGA Institute","name":"copyright","label":"Copyright"}]}}